Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.39 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.37 |
| ▸ | PLK4 | O00444 | 2/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21786536 | 0.79 | PTGER1 (0.41) | SLC6A4PTGER1MRGPRX4PTGDR2TBXA2R | |
| SCHEMBL21786482 | 0.79 | TBXA2R (0.37) | SLC6A4PTGER1MRGPRX4TBXA2R | |
| SCHEMBL21786626 | 0.79 | MAPT (0.39) | MRGPRX4 | |
| SCHEMBL21786597 | 0.79 | MAPT (0.38) | SLC6A4MRGPRX4 | |
| SCHEMBL22791110 | 0.78 | TBXA2R (0.36) | SLC6A4PTGER1MRGPRX4TBXA2R | |
| SCHEMBL21786475 | 0.77 | TBXA2R (0.35) | SLC6A4PTGER1MRGPRX4TBXA2R | |
| SCHEMBL21786594 | 0.77 | CYSLTR1 (0.42) | SLC6A4MRGPRX4NR1H2NR1H3 | |
| SCHEMBL22791109 | 0.77 | CNR1 (0.37) | PTGER1MRGPRX4TBXA2R | |
| SCHEMBL23913056 | 0.76 | TBXA2R (0.35) | PTGER1MRGPRX4TBXA2R | |
| SCHEMBL22791319 | 0.76 | SLC6A4 (0.42) | SLC6A4MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210395206-A1 | SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS | NORTHWESTERN UNIVERSITY | 2021-12-23 | — | — | US | disclosed |
| US-11142504-B2 | Substituted heterocycles as c-MYC targeting agents | NORTHWESTERN UNIVERSITY (US) | 2021-10-12 | — | — | US | disclosed |
| WO-2020257261-A1 | SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS | NORTHWESTERN UNIVERSITY (US) | 2020-12-24 | — | — | WO | disclosed |
| US-20200392116-A1 | SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS | NORTHWESTERN UNIVERSITY (US) | 2020-12-17 | — | — | US | disclosed |
| WO-2020046382-A1 | SUBSTITUTED HETEROCYCLES AS C-MYC TARGETING AGENTS | NORTHWESTERN UNIVERSITY (US) | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392116-A1 | SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS | MYC, MYCBP, MYCBP2 | SLC6A4 4129/4885PTGER1 4862/4885PSD 3716/4885 |
| US-20210395206-A1 | SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS | MYC, MYCBP, MYCBP2 | SLC6A4 4129/4885PTGER1 4862/4885PSD 3716/4885 |
| US-11142504-B2 | Substituted heterocycles as c-MYC targeting agents | MYC, MYCBP, MYCBP2 | SLC6A4 4129/4885PTGER1 4862/4885PSD 3716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.